If sleep problems persist and are bothersome, you should discuss them with your healthcare provider for further advice and potential solutions
Strategies to enhance the tolerability of GLP-1-based therapy might include identification of agents that stimulate release of endogenous GLP-1 from intestinal L-cells, potentially accompanied by fewer adverse effects
Jones and Brierley describe obesity as a chronic, relapsing, and progressive disease
Mild redness, swelling, or discomfort at the injection site is the most commonly reported effect
The efficacy and safety appear to be equivalent between the two methods, even though the interpretation is limited by the small numbers and heterogeneity of selected trials
Elimination kinetics for acetyl-L-carnitine are similar to those for L-carnitine